Revolution Medicines (RVMD) revenue and earnings history
Revolution Medicines reported revenue of $0 for fiscal 2025 (year ended Dec 31, 2025), and net income of −$1.13B.
Revenue and net income, 8 fiscal years
Annual figures, newest first
| Fiscal year | Revenue | Operating income | Net income | Operating cash flow | Capital expenditure | Free cash flow | Stock-based pay | Share buybacks | Dividends paid | Cash at year end | Total debt at year end | Report |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025ended Dec 31, 2025 | $0 | −$1.18B | −$1.13B | −$898M | $16M | −$914M | $118M | — | — | $384M | — | 10-K |
| 2024ended Dec 31, 2024 | $0 |
The latest quarter, insider trades and fund moves: Revolution Medicines (RVMD) on OQRO.
Common questions
What was Revolution Medicines's revenue in fiscal 2025?
$0 for the year ended Dec 31, 2025, as reported in its 10-K filed Feb 25, 2026.
Has Revolution Medicines been profitable?
It reported a net loss in 8 of the years shown (2018, 2019, 2020, 2021, 2022, 2023, 2024, 2025). The highest net income was −$41.8M in fiscal 2018.
What was Revolution Medicines's free cash flow in fiscal 2025?
−$914M: operating cash flow of −$898M minus capital expenditure of $16M. OQRO calculates free cash flow this way from the two filed lines.
Where these figures come from
The SEC’s companyfacts data: every figure Revolution Medicines tagged in XBRL in its annual and quarterly reports since 2009 (some reports carry a few earlier years as comparatives). For each fiscal year OQRO keeps the twelve-month totals from the annual report and the cash and debt at year end, and when a later report restates a year, the later figure. Read again whenever the company files.
Figures are as reported, in US dollars, with no adjustment for acquisitions, disposals or one-off items. Earnings per share are left out because a stock split changes them between reports. This page describes the past and is not investment advice. No language model wrote it.
